Core net profit increased 2.5% (down 3.4% at constant currency) to 775.6 billion yen.

Takeda CEO Christophe Weber said, "Takeda delivered excellent results in FY2024. Our return to Core Operating Profit margin growth underscores the strength of our Growth & Launch Products portfolio and the ability of our multi-year efficiency program to deliver meaningful cost savings.

Revenue was 4.26 trillion yen (around $28.4 billion), up 7.5% (or up 29% at constant currency).

• The increase is attributable to favorable foreign exchange rates and growth from business momentum of Gastroenterology (GI), Rare Diseases, Plasma-Derived Therapies (PDT), Oncology, and Vaccines, partly offset by a decrease in Neuroscience.

Takeda reported the fiscal year 2024 operating profit of 342.6 billion yen, up 60%, and core operating profit of 1.162 trillion yen, up 10.2% (up 4.9% on constant currency).

Also Read: Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer

Takeda expects the potential exposure to U.S. and China tariffs to be limited. It notes:

Guidance: Takeda forecasts its operating profit will reach 475 billion yen in the fiscal year 2025, broadly flat year over year on a constant currency basis.

The company expects revenues of 4.53 trillion yen, reported earnings per share of 145 yen, and core earnings of 485 yen per share.

"FY2025 will be a pivotal year as we invest in launch readiness for the late-stage pipeline, which will contribute to our broadly flat Core Operating Profit outlook for FY2025 but will be key to achieving Takeda's long-term growth potential," Weber said.

Price Action: TAK stock is down 5.2% at $14.26 at last check Thursday.

Read Next:

• Exxon Mobil Says Deal With Japan’s Marubeni To Boost Global Energy Supply

Photo: Gorodenkoff/Shutterstock